daivobet 50 micrograme/0,5mg/g
leo laboratories ltd. - irlanda - combinatii (calcipotriolum+betamethasonum) - unguent - 50micrograme/0,5mg/g - antipsoriazice de uz local alte antipsoriazice de uz local
daivobet 50 micrograme/0,5 mg/g
leo pharma a/s - danemarca - combinatii (calcipotriolum+betamethasonum) - gel - 50micrograme/0,5mg/g - antipsoriazice de uz local alte antipsoriazice de uz local
enstilum 50 micrograme/0,5 mg/g
colep laupheim gmbh & co. kg - germania - combinatii (calcipotriolum+betamethasonum) - spuma cut. - 50micrograme/0,5mg/g - antipsoriazice de uz local alte antipsoriazice de uz local
xamiol 50 micrograme/ 0,5 mg/g
leo pharma a/s - combinatii (calcipotriolum+betamethasonum) - gel - 50micrograme/0,5mg/g - antipsoriazice de uz local alte antipsoriazice de uz local
sorel solutie cutanata 0,05 mg/ml
lek pharmaceuticals d.d./ljubljana - solutie cutanata - 0,05 mg/ml
phorcal unguent 3 mcg/g
kusum healthcare pvt.ltd - calcitriolum - unguent - 3 mcg/g
rocaltrol 0,25 micrograme
roche romania s.r.l. - calcitriolum - caps. moi - 0,25micrograme - vitamina a si d, incl. combinatii vitamina d si analogi
phorcal 3 mcg/g unguent
kusum healthcare pvt.ltd - calcitriolum - unguent - 3 mcg/g
calcium+vitamin d comprimate filmate 500 mg + 200 ui
unipharm inc. - calciu + cholecalciferolum - comprimate filmate - 500 mg + 200 ui
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - medicamente pentru tratamentul bolilor osoase - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.